Date: 2012-01-04
Type of information: Fundraising
Company: Probiodrug (Germany)
Investors:
Amount: €15 Million
Funding type: fundraising
Planned used: This capital raise further strengthens Probiodrug’s financial position and will help the company to advance its lead compound, PQ912, in the clinic towards proof of concept.
Others: Probiodrug has secured €15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program (Glutaminyl cyclase is a novel enzyme target discovered and patented by Probiodrug. It has a crucial role in the pathogenesis of Alzheimer's disease as well as various peripheral inflammatory diseases).The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.
Therapeutic area: Inflammatory diseases - Neurodegenerative diseases
